function
declin
given
close
relationship
exacerb
airway
inflamm
intervent
target
reduc
exacerb
might
also
reduc
airway
inflamm
limit
includ
lack
biolog
specimen
confirm
airway
remodel
direct
measur
medic
complianc
also
unavail
exacerb
data
collect
semiannu
use
patient
recal
prior
month
thu
includ
entir
year
period
data
collect
point
howev
might
caus
potenti
underestim
asthma
exacerb
count
thu
bias
result
toward
null
hypothesi
associ
exacerb
lung
function
declin
summari
longitudin
data
tenor
studi
suggest
asthma
exacerb
acceler
lung
function
declin
extent
possibl
structur
chang
airway
caus
exacerb
subsequ
risk
airway
remodel
requir
studi
find
emphas
import
prevent
exacerb
preserv
lung
function
particularli
younger
popul
editor
asthma
exacerb
secondari
viral
ill
import
caus
morbid
among
children
asthma
allergi
risk
factor
virusinduc
exacerb
although
less
frequent
exacerb
asthma
occur
independ
viral
ill
pattern
caus
asthma
exacerb
investig
crosssect
studi
longitudin
data
lack
sought
determin
whether
separ
group
children
asthma
exacerb
virus
children
asthma
exacerb
without
virus
addit
test
hypothesi
distinct
risk
factor
virusinduc
exacerb
exacerb
associ
viral
infect
childhood
origin
asthma
coast
studi
follow
children
prospect
birth
age
year
follow
age
year
children
met
criteria
asthma
andor
year
age
tabl
subset
coast
children
predominantli
male
fortynin
percent
famili
histori
matern
asthma
histori
patern
asthma
fortyseven
percent
aeroallergen
sensit
age
year
age
year
major
live
home
without
smoke
exposur
year
children
take
daili
control
either
season
perenni
compar
children
year
asthma
exacerb
defin
ill
child
requir
stepup
plan
care
use
oral
corticosteroid
sever
asthma
exacerb
defin
use
oral
corticosteroid
nasal
sampl
collect
asthma
exacerb
analyz
respiratori
tract
virus
respiratori
tract
virus
identifi
use
multiplex
pcr
allergenspecif
ige
level
measur
use
immunocap
phadia
portag
mich
perform
age
year
posit
result
defin
kul
greater
coast
children
asthma
least
exacerb
age
year
exacerb
group
exacerb
caus
children
exacerb
viral
exacerb
nonvir
exacerb
mixtur
viral
nonvir
exacerb
children
exacerb
nasal
sampl
children
viral
nonvir
exacerb
fewer
exacerb
averag
mean
ci
ci
respect
children
experienc
viral
nonvir
exacerb
mean
ci
children
least
exacerb
highest
preval
allerg
sensit
total
ige
level
age
year
see
tabl
articl
onlin
repositori
wwwjacionlineorg
total
exacerb
includ
nasal
sampl
obtain
viral
analysi
virus
identifi
exacerb
rhinoviru
commonli
identifi
exacerb
see
fig
articl
onlin
repositori
wwwjacionlineorg
total
number
exacerb
posit
associ
total
ige
level
age
year
p
incid
rate
ratio
irr
respect
increas
log
ige
fig
final
compar
sever
viral
versu
nonvir
exacerb
twentythre
percent
nonvir
exacerb
viral
exacerb
sever
p
sever
exacerb
nonvir
associ
rhinoviru
infect
associ
virus
greatest
number
sever
exacerb
regardless
caus
occur
fall
octob
novemb
spring
march
see
fig
articl
onlin
repositori
www
jacionlineorg
studi
provid
new
data
pattern
asthma
exacerb
span
cohort
suburban
children
notabl
children
experienc
multipl
episod
least
viral
exacerb
risk
factor
viral
nonvir
asthma
exacerb
similar
consist
indic
atopi
ie
total
ige
aeroallergen
sensit
previou
studi
establish
atopi
risk
factor
virusinduc
wheez
exacerb
asthma
exampl
wheez
ill
children
older
year
common
children
rhinoviru
infect
togeth
allerg
sensit
nasal
eosinophilia
increas
nasal
eosinophil
cation
protein
level
addit
studi
identifi
increas
express
receptor
monocyt
dendrit
cell
acut
asthma
exacerb
one
potenti
mechan
ige
could
affect
viral
exacerb
relat
effect
interferon
respons
vitro
experi
demonstr
increas
express
plasmacytoid
dendrit
cell
ige
crosslink
strongli
inhibit
rhinovirusinduc
interferon
product
cell
children
allerg
asthma
strength
current
studi
includ
longitudin
analysi
exacerb
period
much
current
literatur
evalu
caus
asthma
exacerb
crosssect
perspect
prospect
multipl
year
studi
limit
rel
small
number
children
group
particularli
group
viral
nonvir
exacerb
fact
children
asthma
cohort
studi
rel
mild
diseas
conclus
find
demonstr
atopi
import
risk
factor
viral
nonvir
exacerb
data
consist
clinic
studi
omalizumab
block
igemedi
inflamm
prevent
viral
nonvir
exacerb
children
moderatetosever
asthma
one
implic
find
treatment
aim
reduc
level
ige
perhap
effector
allerg
inflamm
could
repres
common
strategi
reduc
morbid
caus
viral
nonvir
asthma
exacerb
azithromycin
modifi
viral
load
sever
respiratori
syncyti
viru
bronchiol
editor
earli
life
respiratori
syncyti
viru
rsv
bronchiol
major
risk
factor
subsequ
recurr
wheez
asthma
highest
asthma
risk
occur
infant
sever
bronchiol
requir
hospit
hospit
infant
experi
least
addit
wheez
episod
almost
diagnos
asthma
age
year
recent
report
result
proofofconcept
trial
azithromycin
prevent
recurr
wheez
follow
rsv
bronchiol
apwrsv
azithromycin
azm
treatment
infant
hospit
rsv
bronchiol
result
lower
likelihood
subsequ
recurr
wheez
antiinflammatori
effect
azm
detect
studi
rel
placebo
azm
treatment
result
greater
declin
nasal
lavag
level
day
p
howev
mechan
azm
may
exert
protect
effect
remain
uncertain
previou
laboratori
investig
suggest
macrolid
vitro
antivir
activ
pretreat
ex
vivo
human
respiratori
epitheli
cell
azm
clarithromycin
reduc
replic
releas
rsv
rhinoviru
addit
azm
pretreat
reduc
rhinoviru
replic
cystic
fibrosi
bronchial
epitheli
cell
howev
potenti
vivo
antivir
effect
macrolid
investig
human
infect
respiratori
virus
therefor
hypothes
find
azm
reduct
postrsv
recurr
wheez
mediat
least
part
antivir
activ
present
studi
aim
address
research
question
azm
antivir
activ
demonstr
lower
rsv
load
serial
nasal
lavag
sampl
obtain
rsv
bronchiol
potenti
antivir
activ
mediat
reduct
recurr
wheez
detect
proofofconcept
trial
detail
descript
apwrsv
studi
report
elsewher
briefli
random
doublemask
placebocontrol
proofofconcept
trial
involv
infant
rsv
bronchiol
elig
infant
age
month
otherwis
healthi
hospit
first
episod
bronchiol
confirm
rsv
infect
infant
histori
prematur
exclud
studi
treatment
either
azm
oral
suspens
mgkg
daili
day
follow
mgkg
daili
addit
day
oral
placebo
suspens
azm
therapi
well
toler
mild
gastrointestin
advers
event
diarrhea
vomit
abdomin
pain
activ
treatment
phase
record
children
azithromycin
placebo
none
warrant
discontinu
studi
medic
studi
protocol
